Abstract
To study changes in amino acid metabolism and biogenic amines in Parkinson's disease, we set up a prospective study and measured biogenic amines, their main metabolites, and 22 different amino acids, in cerebrospinal fluid of Parkinson's disease patients (n = 24) and age-matched controls (n = 30). A trend toward higher dopamine levels in Parkinson's disease patients was interpreted as an effect of treatment with levodopa and/or selegiline. Significantly lower concentrations of the dopamine metabolite 3,4-dihydroxyphenylacetic acid in the Parkinson's disease group might reflect dopaminergic cell loss. Our results revealed decreased serotonin catabolism that was interpreted as an effect of treatment with selegiline. Whereas all amino acid levels were unchanged, taurine was significantly lower in Parkinson's disease patients. Studies showed that taurine exerts a trophic action on the central nervous system. In this view, decreased taurine in a neurodegenerative disorder as Parkinson's disease deserves attention.
Similar content being viewed by others
REFERENCES
Molina, J. A., Jiménez-Jiménez, F. J., Gómez, P., Vargas, C., Navarro, J. A., Orti-Pareja, M., Gasalla, T., Benito-Léon, J., Bermejo, F., and Arenas, J. 1997. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J. Neurol. Sci. 150:123-127.
Lakke, J. P. and Teelken, A. W. 1976. Amino acid abnormalities in cerebrospinal fluid of patients with Parkinsonism and extrapyramidal disorders. Neurology 26:489-493.
Lakke, J. P., Teelken, A. W., van der Vloet, H., and Wolthers, B. G. 1987. Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries. Adv. Neurol. 45:243-247.
Hare, T. A., Beasley, B. L., Chambers, R. A., Boehme, D. H., and Vogel, W. H. 1973. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA. Clin. Chim. Acta 45:273-280.
Araki, K., Takino, T., Ida, S., and Kuriyama, K. 1986. Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration. Acta Neurol. Scand. 73:105-110.
van Sande, M., Caers, J., and Lowenthal, A. 1971. Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment. Zeitschrift Neurol. 199:24-29.
Gjessing, L. R., Gjesdahl, P., Dietrichson, P., and Presthus, J. 1974. Free amino acids in the cerebrospinal fluid in old age and in Parkinson's disease. Eur. Neurol. 12:33-37.
Espino, A., Ambrosio, S., Bartrons, R., Bendahan, G., and Calopa, M. 1994. Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. J. Neural. Transm. 7:167-176.
Jiménez-Jiménez, F. J., Molina, J. A., Vargas, C., Gómez, P., Navarro, J. A., Benito-León, J., Ortí-Pareja, M., Gasalla, T., Cisneros, E., and Arenas, J. 1996. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 141:39-44.
Hare, T. A., Vanna, S., Beasley, B., Chambers, R., and Vogel, W. H. 1971. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease: J. Lab. Clin. Med. 77:319-325.
Iwasaki, Y., Ikeda, K., Shiojima, T., and Kinoshita, M. 1992. Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease. Neurosci. Lett. 145:175-177.
Tohgi, H., Abe, T., Hashiguchi, K., Takahashi, S., Nozaki, Y., and Kikuchi, T. 1991. A significant reduction of putative neurotransmitter amino acids in CSF of patients with Parkinson's disease and spinocerebellar degeneration. Neurosci. Lett. 126:155-158.
Mally, J., Szalai, G., and Stone, T. W. 1997. Changes in concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 151:159-162.
Zubenko, G. S., Marquis, J. K., Volicer, L., Direnfield, L. K., Langlais, P. J., Nixon, R. A. 1986. Cerebrospinal fluid levels of angiotensin converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: A correlative study. Biol. Psychiatry 21:1365-1381.
Tohgi, H., Abe, T., Takahashi, S., Takahashi, J., and Hamato, H. 1993. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease and their changes after L-dopa administration. Neurosci. Lett. 159:135-138.
Eldrup, E., Mogensen, P., Jacobsen, J., Pakkenberg, H., and Christensen, N. J. 1995. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Acta Neurol. Scand. 92:116-121.
Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., and Agid, Y. 1983. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275:321-328.
Mena, M. A., Aguado, E. G., and De Yebenes, J. G. 1984. Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. Acta Neurol. Scand. 69:218-225.
Johansson, B. and Roos, B. E. 1969. 5-Hydroxyindoleacetic acid and homovanillic acid levels in the cerebrospinal fluid of health volunteers and patients with Parkinson's disease. Life Sci. 6:1449-1454.
LeWitt, P. A., Galloway, M. P., Matson, W., Milbury, P., Mc-Dermott, M., Srivastava, D. K., and Oakes, D. 1992. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology 42:2111-2117.
Riederer, P., Birkmayer, W., Steemann, D., and Wuketich, S. 1977. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J. Neural. Transm. 41:241-251.
Teychenne, P. F., Lake, C. R., and Ziegler, M. G. 1980. Cerebrospinal fluid studies in Parkinson's disease. Pages 197-206, in Wood, J. H. (ed.), Neurobiology of cerebrospinal fluid, Plenum Press, New York.
Chan-Palay, V. and Asan, E. 1989. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287:373-392.
Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G., and Nappi, G. 1992. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural. Transm. 4:191-205.
Turkka, J. T., Juujärvi, K. K., and Myllylä, V. V. 1987. Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease. Eur Neurol. 26:29-34.
Chase, T. N. 1972. Serotonergic mechanisms in Parkinson's disease. Arch. Neurol. 27:354-356.
Hinterberger, H. and Andrews, C. J. 1972. Catecholamine metabolism during oral administration of levodopa. Arch. Neurol. 26:245-252.
Davidson, D. L., Yates, D. L., Mawdsley, C., Pullar, I. A., and Wilson, H. 1977. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in parkinsonism and other movement disorders. J. Neurol. Neurosurg. Psychiatry, 40: 1136-1141.
Volicer, L., Direnfeld, L. K., Freedman, M., Albert, M. L., Langlais, P. J., and Bird, E. D. 1985. Serotonin and 5-hydroxy-indoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. Arch. Neurol. 42:127-129.
Pullar, I. A., Weddell, J. M., Ahmed, R., and Gillingham, F. J. 1970. Phenolic acid concentration in the lumbar cerebrospinal fluid of parkinsonian patients treated with L-Dopa. J. Neurol. Neurosurg. Psychiatry 33:851-857.
Van Woert, M. H. and Bowers, M. B. 1970. The effect of L-DOPA on monoamine metabolites in Parkinson's disease. Experientia 26:161-163.
Tohgi, H., Abe, T., Takahashi, S., Nozaki, Y., Ueno, M., and Kikuchi, T. 1992. Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: Relationship to clinical symptoms and subsequent therapeutic outcomes. J. Neural. Transm. P.D. Sect. 5:17-26.
Mayeux, R., Stern, Y., Sano, M., Williams, J. B., and Cote, L. J. 1988. The relationship of serotonin to depression in Parkinson's disease. Mov. Disord. 3:237-244.
Chan-Palay, V. 1993. Depression and dementia in Parkinson's disease: Catecholamine changes in the locus coeruleus, a basis for therapy. Adv. Neurol. 60:438-446.
Hoehn, M. M. and Yahr, M. D. 1967. Parkinsonism: Onset, progression and mortality. Neurology 17:427-442.
Pei, H. 1994. The use of cation exchange resin in analytical research of amino acids. Dissertation to obtain the degree of Master in Biomedical Sciences, University of Antwerp(U.I.A.), Belgium.
Folstein, M., Folstein, S., and McHugh, P. R. 1975. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:189-196.
Tyce, G. M., Messick, J. M., Yaksh, T. L., Byer, D. E., Danielson, D. R., and Rorie, D. K. 1986. Amine sulfate formation in the central nervous system. Fed. Proc. 45:2247-2253.
Eldrup, E., Hagen, C., Christensen, N. J., and Ølgaard, K. 1988. Plasma free and sulfoconjugated dopamine in man: Relationship to sympathetic activity, adrenal function and meals. Dan. Med. Bull. 35:291-294.
Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Camp, D. M., DeMaggio, A. J., Havaich, M. K., Milbury, P. E., and Matson, W. R. 1998. Influence of repeated levodopa administration on rabbit striatal serotonin metabolism and comparison between striatal and CSF alterations. Neurochem. Res. 23: 1521-1525.
Rozas, G., Liste, I., Guerra, M. J., and Labandeira-Garcia, J. L. 1998. Sprouting of serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci. Lett. 245:151-154.
Dawson, R. Jr., Pelleymounter, M. A., Cullen, M. J., Gollub, M., and Liu, S. 1999. An age-related decline in striatal taurine is correlated with a loss of dopaminergic markers. Brain Res. Bull. 48:319-324.
Kowall, N. W. and Beal, M. F. 1991. Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 29:162-167.
Alom, J., Mahy, J. N., Brandi, N., and Tolosa, E. 1991. Cerebrospinal fluid taurine in Alzheimer's disease. Ann. Neurol. 30:735.
Pomara, N., Singh, R., Deptula, D., Chou, J. C., Schwartz, M. B., and LeWitt, P. A. 1992. Glutamate and other CSF amino acids in Alzheimer's disease. Am. J. Psychiatry 149:251-254.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Engelborghs, S., Marescau, B. & De Deyn, P.P. Amino Acids and Biogenic Amines in Cerebrospinal Fluid of Patients with Parkinson's Disease. Neurochem Res 28, 1145–1150 (2003). https://doi.org/10.1023/A:1024255208563
Issue Date:
DOI: https://doi.org/10.1023/A:1024255208563